Prescient Therapeutics (ASX:PTX) granted key US patent for OmniCar platform
Prescient Therapeutics (PTX) has been granted a key US patent for its OmniCAR universal immune...
Prescient Therapeutics (PTX) has been granted a key US patent for its OmniCAR universal immune...
Prescient Therapeutics (PTX) has opened patient enrolments for an expanded phase 1B trial of its...
Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs...
Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell &...
Prescient Therapeutics (PTX) has summarised its operations and cashflow for the June quarter. The clinical-stage...
Prescient Therapeutics (PTX) is progressing the trial of its cancer-blocking drug PTX100 following successful results...
Prescient Therapeutics (PTX) says recent results from testing show its entire platform has been substantially...
Prescient Therapeutics (PTX) has slipped on the ASX today despite announcing some key developments for...
Prescient Therapeutics (PTX) has announced a new research program with the Peter MacCallum Cancer Centre...
Prescient Therapeutics (PTX) will progress to the next dose level of its Phase 1b clinical...
To stay up to date with Prescient Therapeutics news and events, please register your details.